HER2+ Gastric Cancer Pipeline: 20+ Players, Clinical & Non-Clinical Studies, Emerging Therapies, And Treatment Landscape Jiangsu Hengrui Medicine, Pieris Pharmaceuticals, Bioinvent International

(MENAFN- GetNews)


"HER2+ Gastric Cancer Companies are AstraZeneca, Shanghai JMT-Bio, Acepodia Biotech, Klus Pharma, Carisma Therapeutics, Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio, Shanghai Miracogen, Bavarian Nordic"DelveInsight's,“HER2 Positive Gastric Cancer - Pipeline Insight, 2025,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in HER2 Positive Gastric Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

With HER2-positive gastric cancer contributing significantly to global cancer morbidity and mortality, there remains a critical need for more effective and targeted therapies. Addressing this unmet need, DelveInsight's“HER2+ Gastric Cancer Pipeline Insight 2024” report offers a detailed analysis of the dynamic therapeutic landscape, spotlighting 20+ key pharmaceutical and biotech players involved in the development of 20+ innovative treatment candidates.

The report provides a comprehensive assessment of clinical and non-clinical studies, emerging drug profiles, trial phase progression, mechanism of action, and recent strategic developments. It also evaluates the current treatment algorithm, identifies unmet needs, and explores future growth opportunities in the HER2+ Gastric Cancer Therapeutics Market.

Request for a HER2+ gastric cancer pipeline insights 2024 report @

Key Takeaways from the HER2+ Gastric Cancer Pipeline Report

• DelveInsight's HER2+ Gastric Cancer pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for HER2+ Gastric Cancer treatment.

• In July 2024, Merck & Co. announced that the Phase III KEYNOTE-811 trial achieved its dual primary endpoint of overall survival. The study evaluated Keytruda in combination with trastuzumab and chemotherapy containing fluoropyrimidine and platinum for the first-line treatment of patients with HER2-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

• In April 2024, ENHERTU (fam-trastuzumab deruxtecan-nxki) received approval in the US as the first tumor-agnostic HER2-targeted therapy for patients with metastatic HER2-positive solid tumors who have undergone prior treatment.

• Key companies in the HER2+ Gastric Cancer treatment landscape include Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo, AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc, Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc., Bavarian Nordic, and others.

• Promising HER2+ Gastric Cancer pipeline therapies in various stages of development include SHR-A1811, Cinrebafusp alfa, BI-1607, and others.

HER2+ Gastric Cancer Overview:

Gastric cancer ranks as the sixth most common cancer globally and the third leading cause of cancer-related deaths. Early-stage gastric cancer is often asymptomatic, with most symptoms appearing only in advanced stages. Common late-stage symptoms include unexplained weight loss, stomach pain, loss of appetite, difficulty swallowing, fatigue, nausea, vomiting, heartburn, and indigestion. Gastric cancer develops due to genetic mutations in stomach cells, causing abnormal cell growth and tumor formation.

A subset of gastric cancers is HER2-positive, characterized by overexpression of the HER2 protein, which promotes tumor growth. HER2, a member of the EGFR family, is encoded by a gene located on chromosome 17 (17q21). HER2-positive cancers can benefit from targeted therapies that inhibit the HER2 protein, though only a minority of patients achieve a cure through surgical resection, with many experiencing recurrence.

The HER2 protein, also known as ErbB2/Neu, is a 185 kDa transmembrane glycoprotein with three key components: an extracellular ligand-binding domain, a transmembrane domain, and an intracellular tyrosine kinase domain. Advances in HER2-targeted treatments provide a promising approach for managing HER2-positive gastric cancers.

Request for detailed information on HER2+ gastric cancer pipeline insights report @

HER2+ Gastric Cancer Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the HER2+ Gastric Cancer Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HER2+ Gastric Cancer treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the HER2+ Gastric Cancer market.

HER2 Positive Gastric Cancer Emerging Drugs

• SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.

• Cinrebafusp alfa: Pieris Pharmaceuticals

• BI-1607: BioInvent International

HER2+ Gastric Cancer Companies

Approximately 20 or more key companies are actively developing therapies for HER2-positive gastric cancer. Among these, Jiangsu HengRui Medicine Co., Ltd. has drug candidates in the most advanced stage of development, specifically Phase III clinical trials.

DelveInsight's report covers around 22+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

HER2+ Gastric Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

HER2+ Gastric Cancer Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging HER2+ Gastric Cancer Therapies and Key Companies: HER2+ Gastric Cancer Clinical Trials and advancements

HER2+ Gastric Cancer Pipeline Therapeutic Assessment

. HER2+ Gastric Cancer Assessment by Product Type

. HER2+ Gastric Cancer By Stage

. HER2+ Gastric Cancer Assessment by Route of Administration

. HER2+ Gastric Cancer Assessment by Molecule Type

Download HER2+ Gastric Cancer Sample report to know in detail about the HER2+ Gastric Cancer treatment market @ HER2+ Gastric Cancer Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. HER2+ Gastric Cancer Current Treatment Patterns

4. HER2+ Gastric Cancer - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. HER2+ Gastric Cancer Late-Stage Products (Phase-III)

7. HER2+ Gastric Cancer Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. HER2+ Gastric Cancer Discontinued Products

13. HER2+ Gastric Cancer Product Profiles

14. HER2+ Gastric Cancer Key Companies

15. HER2+ Gastric Cancer Key Products

16. Dormant and Discontinued Products

17. HER2+ Gastric Cancer Unmet Needs

18. HER2+ Gastric Cancer Future Perspectives

19. HER2+ Gastric Cancer Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the HER2+ Gastric Cancer Pipeline Reports Offerings:

MENAFN23062025003238003268ID1109713110